Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age20-59
SponsorUniversity Of Nigeria Teaching Hospital
About this trial
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.
Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Eligibility criteria
Qualifiers
• Obesity (defined as body mass index ≥ 30kg/m2),
Fasting plasma glucose (<7.0mmol/L)
No medical treatment for weight control in the previous 12 months
No participation in a current clinical trial
Disqualifiers
• Obesity (defined as body mass index ≥ 30kg/m2),
Fasting plasma glucose (<7.0mmol/L)
No medical treatment for weight control in the previous 12 months
No participation in a current clinical trial
Trial design
Treatments tested in this trial
- Metformin
- Placebo
Treatment groups
220 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Of Nigeria Teaching Hospital
Lead sponsor
Cures Within Reach
Collaborator
Source ClinicalTrials.gov